SecBot SecBot
SECBOTREPLAY Home › Report › INM

INM · InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid…

InMed Pharmaceuticals Inc. · 8-K filed Jun 10, 2026 at 06:01 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Jun 10, 2026 at 06:01 ET

InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, closing a delisting notice received on March 27, 2026. The company demonstrated a closing bid price at or above $1.00 for 10 consecutive business days through June 2, 2026. This is a procedural compliance update, it removes an immediate delisting overhang but does not change the company's operational or financial trajectory.

  • InMed received a Nasdaq deficiency notice on March 27, 2026 for non-compliance with the $1.00 bid price rule (Rule 5550(a)(2))
  • Nasdaq confirmed compliance on June 3, 2026, based on 10 consecutive business days (May 19–June 2, 2026) with closing bid at or above $1.00
  • The matter is now closed with no further action required by Nasdaq
  • Company has a market cap of ~$4M and analyst consensus is 0% bullish (3 Hold, 4 Sell, 1 Strong Sell)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access